FDA news. Price criticized for new anti-HIV drug.
The FDA approved a new class of anti-HIV drugs that will benefit patients whose virus has become resistant to other treatments. But as states are facing funding shortfalls for AIDS drug assistance programs, activists say most patients won't be able to afford the drug.
D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000191:economics* / Q000494:pharmacology; D023581:HIV Fusion Inhibitors / Q000191:economics* / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D008561:Membrane Fusion / Q000187:drug effects; D010446:Peptide Fragments / Q000191:economics* / Q000494:pharmacology; D014481:United States; D014486:United States Food and Drug Administration
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide